Video

Personalized Medicine in Colorectal Cancer

For High-Definition, Click

Personalized medicine in colorectal cancer has lagged behind the breakthroughs experienced in other disease types, such as criztonib and erlotinib in lung cancer, suggest moderator John L. Marshall, MD. As the field continues to evolve, next-generation sequencing will likely play a larger role to identify patients for clinical trials, Fadi Braiteh, MD, CPI, believes.

In some cases, if a patient knows they have a specific mutation, they may ask to be treated with a targeted therapy that is approved for another indication, Axel Grothey, MD, states. In these situations, if the drug is administered, whether off-label or on a clinical trial, careful documentation is needed to demonstrate a difference in patient outcome.

Depending on the institution and test, a rebiopsy of the lesion may be required in order to gain an accurate genetic profile. In these situations, the cost-benefit ratios need to be considered to see if the additional costs associated with these procedures are warranted by potential improvements in outcome, says Tanios Bekaii-Saab, MD. At this point, these molecular tests primarily help to determine eligibility for clinical trials.

There are several questions that still need answered before the widespread use of next-generation sequencing is put into practice, states Alan P. Venook, MD. In general, it is unlikely that a single mutation is responsible for tumor growth in colorectal cancer. As a result, Venook suggests, future research will need to focus on targeted combinations against multiple alterations.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma
Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Jun 19th 2025 - Jul 25th 2025

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity